GDS Wealth Management Makes New Investment in HealthEquity, Inc. (NASDAQ:HQY)

GDS Wealth Management bought a new position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 28,638 shares of the company's stock, valued at approximately $2,344,000.

Several other hedge funds have also recently modified their holdings of HQY. Motley Fool Asset Management LLC raised its holdings in shares of HealthEquity by 3,001.0% during the 1st quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company's stock worth $307,097,000 after acquiring an additional 3,640,748 shares in the last quarter. Mackenzie Financial Corp lifted its position in HealthEquity by 16.0% during the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company's stock valued at $203,822,000 after purchasing an additional 325,906 shares during the last quarter. Generate Investment Management Ltd bought a new position in HealthEquity during the second quarter valued at $24,184,000. Thrivent Financial for Lutherans grew its stake in shares of HealthEquity by 924.2% in the 2nd quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company's stock worth $18,983,000 after buying an additional 198,718 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of HealthEquity by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company's stock worth $715,783,000 after buying an additional 149,133 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Barrington Research reaffirmed an "outperform" rating and issued a $105.00 price target on shares of HealthEquity in a report on Friday, September 20th. Bank of America cut their target price on HealthEquity from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, September 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $92.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. JMP Securities reissued a "market outperform" rating and issued a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of HealthEquity from $102.00 to $103.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $103.83.

Insider Transactions at HealthEquity

In related news, Director Frank Corvino sold 1,039 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the sale, the director now owns 3,784 shares of the company's stock, valued at $363,642.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Frank Corvino sold 1,039 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the completion of the transaction, the director now directly owns 3,784 shares of the company's stock, valued at $363,642.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the business's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now directly owns 54,719 shares in the company, valued at approximately $4,540,582.62. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 10,536 shares of company stock valued at $884,517. Corporate insiders own 2.20% of the company's stock.

HealthEquity Stock Up 1.4 %

Shares of HealthEquity stock traded up $1.40 during trading on Monday, hitting $100.22. 275,306 shares of the stock traded hands, compared to its average volume of 614,448. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock's fifty day simple moving average is $83.15 and its 200 day simple moving average is $80.45. The firm has a market cap of $8.75 billion, a P/E ratio of 82.35, a price-to-earnings-growth ratio of 1.55 and a beta of 0.52. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $100.97.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million during the quarter, compared to analyst estimates of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. On average, equities analysts predict that HealthEquity, Inc. will post 2.27 earnings per share for the current fiscal year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.